INVASIVE FUNGAL INFECTION AMONG FEBRILE PATIENTS WITH CHEMOTHERAPY-INDUCED NEUTROPENIA IN THAILAND

被引:0
|
作者
Phikulsod, Ployploen [1 ]
Suwannawiboon, Bundarika [1 ]
Chayakulkeeree, Methee [2 ]
机构
[1] Siriraj Hosp, Fac Med, Dept Med, Div Hematol, 2 Prannok St,Chalermprakiat Bldg, Bangkok 10700, Thailand
[2] Siriraj Hosp, Fac Med, Dept Med, Div Infect Dis, Bangkok, Thailand
关键词
febrile neutropenia; invasive fungal infection; risk factor; incidence; chemotherapy; ASPERGILLOSIS; DISEASE; EPIDEMIOLOGY; HEMATOLOGY;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Invasive fungal infections (IFI) can cause serious morbidity and mortality among febrile patients with chemotherapy-induced neutropenia (CIN). In order to evaluate the incidence, treatment outcome and factors associated with IFI in this patient population in Thailand, we retrospectively reviewed the medical record of patients admitted to Siriraj Hospital from January 2008 to June 2010. Criteria used to diagnosed IFI were those of the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases/Mycoses Study Group (EORTC/MSG) consensus 2008 criteria. Three hundred ten episodes of chemotherapy-induced neutropenia occurred in 233 patients. IFI were found in 37 episodes (12%) and occurred only in patients who received chemotherapy for hematological malignancies. The incidence of IFI among patients with hematologic malignancies was 14%. Most commonly occurred in AML patients (17%). Patients who received aggressive induction chemotherapy regimens for AML had the highest incidence of IFI (20.5%). Of the 37 episodes, 12 were candidiasis, 5 were aspergillosis, 1 was zygomycosis, 1 was fusariosis, 10 were probable and 9 were possible IFI. The IFI-related mortality was 35%. The clinical factor associated with IFI was a temperature > 39 degrees C during febrile neutropenia. A higher mortality rate was seen in patients aged > 40 years and those with a serum albumin level < 3 g/dl.
引用
收藏
页码:159 / 169
页数:11
相关论文
共 50 条
  • [41] Colony-stimulating factors: Clinical evidence for treatment and prophylaxis of chemotherapy-induced febrile neutropenia
    Raposo C.G.
    Marín Á.P.
    Barón M.G.
    Clinical and Translational Oncology, 2006, 8 (10) : 729 - 734
  • [42] Value of incorporating newly identified risk factors into risk prediction for chemotherapy-induced febrile neutropenia
    Li, Yanli
    Family, Leila
    Chen, Lie H.
    Page, John H.
    Klippel, Zandra
    Xu, Lanfang
    Chao, Chun R.
    CANCER MEDICINE, 2018, 7 (08): : 4121 - 4131
  • [43] Evaluating the total costs of chemotherapy-induced febrile neutropenia: Results from a pilot study with community oncology cancer patients
    Bennett, Charles L.
    Calhoun, Elizabeth A.
    ONCOLOGIST, 2007, 12 (04) : 478 - 483
  • [44] A prospective, randomized study of empirical antifungal therapy for the treatment of chemotherapy-induced febrile neutropenia in children
    Caselli, Desiree
    Cesaro, Simone
    Ziino, Ottavio
    Ragusa, Pietro
    Pontillo, Alfredo
    Pegoraro, Anna
    Santoro, Nicola
    Zanazzo, Giulio
    Poggi, Vincenzo
    Giacchino, Mareva
    Livadiotti, Susanna
    Melchionda, Fraia
    Chiodi, Marcello
    Arico, Maurizio
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 158 (02) : 249 - 255
  • [45] Chemotherapy-induced neutropenia among breast Cancer patients in a tertiary care hospital: Risk and consequences
    Joseph, Anu
    Joshua, Julie Mariam
    Mathews, Santhosh M.
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (03) : 529 - 533
  • [46] Evaluating the Prognostic Role of Monocytopenia in Chemotherapy-Induced Febrile Neutropenia Patients Treated with Granulocyte Colony-Stimulating Factor
    Alshari, Osama
    Al Zu'bi, Yazan O.
    Al Sharie, Ahmed H.
    Wafai, Farouk H.
    Aleshawi, Abdelwahab J.
    Atawneh, Farah H.
    Obeidat, Hasan A.
    Daoud, Majd N.
    Khrais, Mohammad Z.
    Albals, Dima
    Tubaishat, Faize
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2021, 17 : 963 - 973
  • [47] Granulocyte colony-stimulating factor (filgrastim) in chemotherapy-induced febrile neutropenia
    Advani, S. H.
    Achreckar, Suvarna
    Thomas, Dennis
    Krishnankutty, Binny
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2010, 31 (03) : 79 - 82
  • [48] Optimal dose of amikacin in childhood chemotherapy-induced febrile neutropenia: Beware of underdosing
    Lesieur, T.
    Goyer, I.
    Bourgine, J.
    Bodet, D.
    Cesbron, A.
    Deparis, M.
    Loilier, M.
    Rouger, J.
    Lelong-Boulouard, V.
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 : 179 - 180
  • [49] Chemotherapy Induced Neutropenia, Febrile-Neutropenia and Determinants Among Solid Cancer Patients Attending Oncology Unit of a Tertiary Care Teaching Hospital in Ethiopia
    Dessalegn, Mekonnen
    Fantahun, Mengistu
    Yesufe, Abdu Adem
    Hussein, Mintewab
    Tsegaye, Aster
    CANCER MANAGEMENT AND RESEARCH, 2023, 15 : 185 - 195
  • [50] Lipegfilgrastim for prophylaxis of chemotherapy-induced neutropenia in Dutch patients
    Timmer-Bonte, J. N. H.
    Ouwerkerk, J.
    Faber, L. M.
    Kerkhofs, L. G. M.
    Laterveer, L.
    ten Oever, D.
    van Rees, B. P.
    van der Linden, P. W.
    NETHERLANDS JOURNAL OF MEDICINE, 2020, 78 (05) : 270 - 276